With an extensive presence in North America, Europe, South America, Australia, New Zealand and South Africa and more recently in the MENA and ASEAN regions, Accord Healthcare has very rapidly become one of the fastest growing generic pharmaceutical companies. With a robust product portfolio in growth segments, such as Oncology, Cardiology, Neurology, Nephrology, Urology, Psychiatry, Diabetology, Pain management and Gastroenterology, Accord's marketing and distribution network now reaches over 70 countries. Accord has grown both organically and via acquisition, expanding its product portfolio and operations in various parts of the world. Our North America and European operations were started with a strategic vision to create a global brand in the world's largest pharmaceutical markets, supported by a commercial infrastructure that enables us to bring our high quality yet affordable products to patients. Today, the company is marketing over 400 molecules and this number is set to increase significantly over the next few years as a result of a segment leading pipeline and strong in house development capability. Our large and growing portfolio allows us to compete with some of the biggest players in the industry. Accord is committed to uncompromised quality for its products and services across the globe. Our products are manufactured under the highest international standards and our manufacturing plants are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA. Increasingly Accord is investing in higher barrier to entry developments such as Biosimilar and New Chemical Entities and is set to evolve into a leading global healthcare provider.